

# Unlocking Insights in Autoimmune diseases treatment Janus Kinase Inhibitors (JAKi)

MARCH 2024


Our latest Autoimmune diseases study features an **extensive and representative cohort**, with **over 26.500 patients** in MAT March 2024, of whom **1.271 were treated with JAKi**, ensuring robust and reliable data.

**The complete study evaluates the entire Autoimmune diseases treatment market, providing the following analyses:**

- **Therapeutic line analysis:** patient distribution across treatment lines in each therapeutic area (Rheumatology, Gastroenterology, Dermatology and External patients), enables informed decisions about the most appropriate and cost-effective treatment options, leading to improved patient outcomes and optimized resource allocation.
- **Patient dynamics:** Reveal movement patterns (new patients, switch dynamics...), uncovering trends and identifying strategic opportunities.
- **Therapeutic class Analysis:** Market analysis by therapeutic class, increasing granularity and facilitating benchmarking within the class.

# Rheumatology

MAT March 2024



The complete study comprises:


**8.283** total patients with Autoimmune diseases treated in Rheumatology specialty

**793** patients treated with JAKi

In the **JAKi submarket** the following results were obtained:


- Xeljanz® holds the highest share with 35,2%
- Most patients are in the age range of 40-59 years (46,5%)
- Within this specialty, JAKi are primarily used as second-line therapy (36,8%)

## Patient share<sup>1</sup>




1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

## Age Distribution




## Therapeutic Line Distribution



# Gastroenterology

MAT March 2024



The complete study comprises:


**7.758** total patients with Autoimmune diseases treated in Gastroenterology specialty

**227** patients treated with JAKi

In the **JAKi submarket** the following results were obtained:


- Xeljanz® holds the highest share with 59,0%
- Most patients are in the age range of 15-39 years (48,1%)
- Within this specialty, JAKi are primarily used as second-line therapy (32,6%)

## Patient share<sup>1</sup>




1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

## Age Distribution




## Therapeutic Line Distribution



# External

MAT March 2024



The complete study comprises:


**5.938** total patients with Autoimmune diseases whose prescription comes from the private sector

**277** patients treated with JAKi

In the **JAKi submarket** the following results were obtained:


- Rinvoq® holds the highest share with 41,2%
- Most patients are in the age range of 40-59 years (49,6%)
- Within this specialty, JAKi are primarily used as first-line therapy (57,0%)

## Patient share<sup>1</sup>




1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

## Age Distribution



## Therapeutic Line Distribution



# Technical File

## SCOPE

Obtain an overview of the population receiving treatment for Autoimmune diseases in Portugal, evaluating the performance of individual drugs within the class of Janus Kinase Inhibitors for autoimmune diseases.

## PERIOD

April 2023 – March 2024

## MEASURES & METRICS

Patient-Level Hospital Consumption Records from the HMR Hospital Database, compliant with anonymisation requirements.

## MARKET SELECTION & ASSUMPTIONS

Drugs used to treat Autoimmune diseases within - ATC Class “L04 – Immunosuppressants”